Emerging role of Natural killer cells in oncolytic virotherapy

References

• DePaceNSulla scomparsa di un enorme vegetante del collo dell’utero senza cura chirugica cancroLa Ginecologia191298288 Italian
   Google Scholar
• PowerABellJCCell-based delivery of oncolytic viruses: a new strategic alliance for a biological strike against cancerMol Ther200715466066517264852
   PubMed Web of Science ®Google Scholar
• WollerNGürlevikEUrecheCISchumacherAKühnelFOncolytic viruses as anticancer vaccinesFront Oncol2014418825101244
   PubMedGoogle Scholar
• NüeschJPRommelaereJTumor suppressing properties of rodent parvovirus NS1 proteins and their derivativesAdv Exp Med Biol20148189912425001533
   PubMed Web of Science ®Google Scholar
• NüeschJPLacroixJMarchiniARommelaereJMolecular pathways: rodent parvoviruses – mechanisms of oncolysis and prospects for clinical cancer treatmentClin Cancer Res201218133516352322566376
   PubMed Web of Science ®Google Scholar
• PaglinoJCAndresWvan den PolANAutonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cellsJ Virol20148894932494224554651
   PubMed Web of Science ®Google Scholar
• MoehlerMGoepfertKHeinrichBOncolytic virotherapy as emerging immunotherapeutic modality: potential of parvovirus H-1Front Oncol2014149224822170
   PubMedGoogle Scholar
• GeletnekyKHuesingJRommelaereJPhase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocolBMC Cancer2012129922436661
   PubMed Web of Science ®Google Scholar
• CerulloVPesonenSDiaconuIOncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patientsCancer Res201070114297430920484030
   PubMed Web of Science ®Google Scholar
• MelcherAParatoKRooneyCMBellJCThunder and lightning: immunotherapy and oncolytic viruses collideMol Ther20111961008101621505424
   PubMed Web of Science ®Google Scholar
• Alvarez-BreckenridgeCAYuJKaurBCaligiuriMAChioccaEADeciphering the multifaceted relationship between oncolytic viruses and natural killer cellsAdv Virol2012201270283922312364
   PubMedGoogle Scholar
• MarcusAGowenBGThompsonTWRecognition of tumors by the innate immune system and natural killer cellsAdv Immunol20141229112824507156
   PubMed Web of Science ®Google Scholar
• HerbermanRBNunnMELavrinDHNatural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificityInt J Cancer19751621622950294
   PubMed Web of Science ®Google Scholar
• KiesslingRKleinEWigzellH‘‘Natural’’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotypeEur J Immunol197551121171234049
   PubMed Web of Science ®Google Scholar
• YuJFreudAGCaligiuriMALocation and cellular stages of natural killer cell developmentTrends Immunol2013341257358224055329
   PubMed Web of Science ®Google Scholar
• VosshenrichCADi SantoJPDevelopmental programming of natural killer and innate lymphoid cellsCurr Opin Immunol20132513013823490162
   PubMed Web of Science ®Google Scholar
• BelloraFCastriconiRDonderoAHuman NK cells and NK receptorsImmunol Lett2014161216817324361820
   PubMed Web of Science ®Google Scholar
• HöglundPBrodinPCurrent perspectives of natural killer cell education by MHC class I moleculesNat Rev Immunol2010101072473420818413
   PubMed Web of Science ®Google Scholar
• PegramHJAndrewsDMSmythMJDarcyPKKershawMHActivating and inhibitory receptors of natural killer cellsImmunol Cell Biol201189221622420567250
   PubMed Web of Science ®Google Scholar
• OrrMTLanierLLNatural killer cell education and toleranceCell2010142684785620850008
   PubMed Web of Science ®Google Scholar
• IvarssonMAMichaëlssonJFauriatCActivating killer cell Ig-like receptors in health and diseaseFront Immunol201422518424795726
   PubMed Web of Science ®Google Scholar
• AmesEMurphyWJAdvantages and clinical applications of natural killer cells in cancer immunotherapyCancer Immunol Immunother2014631212823989217
   PubMed Web of Science ®Google Scholar
• LiaoWLinJXLeonardWJInterleukin-2 at the crossroads of effector responses, tolerance, and immunotherapyImmunity2013381132523352221
   PubMed Web of Science ®Google Scholar
• OchoaMCMazzoliniGHervas-StubbsSde SanmamedMFBerraondoPMeleroIInterleukin-15 in gene therapy of cancerCurr Gene Ther2013131153023157547
   PubMed Web of Science ®Google Scholar
• AmesEHallettWHMurphyWJSensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibitionClin Exp Immunol2009155350451319220837
   PubMed Web of Science ®Google Scholar
• RomagnéFAndréPSpeePPreclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cellsBlood2009114132667267719553639
   PubMed Web of Science ®Google Scholar
• WelniakLABlazarBRMurphyWJImmunobiology of allogeneic hematopoietic stem cell transplantationAnnu Rev Immunol20072513917017129175
   PubMed Web of Science ®Google Scholar
• RuggeriLCapanniMUrbaniEEffectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplantsScience200229555622097210011896281
   PubMed Web of Science ®Google Scholar
• LocatelliFMorettaFBresciaLMerliPNatural killer cells in the treatment of high risk acute leukaemiaSemin Immunol20142617317924613727
   PubMed Web of Science ®Google Scholar
• ChengMMaJChenYEstablishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell lineCell Transplant20112011–121731174621669033
   PubMed Web of Science ®Google Scholar
• BhatRWatzlCSerial killing of tumor cells by human natural killer cells – enhancement by therapeutic antibodiesPLoS One200723e32617389917
   PubMed Web of Science ®Google Scholar
• JahnTZutherMFriedrichsBAn IL12-IL2-antibody fusion protein targeting Hodgkin’s lymphoma cells potentiates activation of NK and T cells for an anti-tumor attackPLoS One20127e4448223028547
   PubMed Web of Science ®Google Scholar
• MorettaLPietraGMontaldoEHuman NK cells: from surface receptors to the therapy of leukemias and solid tumorsFront Immunol201458724639677
   PubMed Web of Science ®Google Scholar
• BalsamoMManziniCPietraGHypoxia down regulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCCEur J Immunol201343102756276423913266
   PubMed Web of Science ®Google Scholar
• AltomonteJWuLChenLExponential enhancement of oncolytic vesicular stomatitis virus potency by vextor-mediated suppression of inflammatory responses in vivoMol Ther200816114615318071337
   PubMed Web of Science ®Google Scholar
• AltomonteJWuLMeseckMEnhanced oncolytic potency of vesicular stomatitis virus through vector-mediated inhibition of NK and NKT cellsCancer Gene Ther200916326627818846115
   PubMed Web of Science ®Google Scholar
• Alvarez-BreckenridgeCAYuJPriceRNK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptorsNat Med201218121827183423178246
   PubMed Web of Science ®Google Scholar
• WeibelSRaabVYuYAViral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infectionBMC Cancer2011116821320309
   PubMed Web of Science ®Google Scholar
• MoralèsORichardAMartinNActivation of a helper and not regulatory human CD4+ T cell response by oncolytic H-1 parvovirusPLoS One201272e3219722359669
   PubMed Web of Science ®Google Scholar
• MillerCGFraserNWRequirement of an integrated immune response for successful neuroattenuated HSV-1 therapy in an intracranial metastatic melanoma modelMol Ther20037674174712788647
   PubMed Web of Science ®Google Scholar
• BenenciaFCourrègesMCConejo-GarcíaJRHSV oncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancerMol Ther200512578980215925544
   PubMed Web of Science ®Google Scholar
• ZhaoQZhangWNingZA novel oncolytic herpes simplex virus type 2 has potent anti-tumor activityPLoS One201493e9310324671154
   PubMed Web of Science ®Google Scholar
• WhiteCLTwiggerKRVidalLCharacterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trialGene Ther2008151291192018323793
   PubMed Web of Science ®Google Scholar
• GujarSAPanDAMarcatoPGarantKALeePWOncolytic virus-initiated protective immunity against prostate cancerMol Ther201119479780421245852
   PubMed Web of Science ®Google Scholar
• RintoulJLLemayCGTaiLHORFV: a novel oncolytic and immune stimulating parapoxvirus therapeuticMol Ther20122061148115722273579
   PubMed Web of Science ®Google Scholar
• MiyamotoSInoueHNakamuraTCoxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinomaCancer Res201272102609262122461509
   PubMed Web of Science ®Google Scholar
• AllenCVongpunsawadSNakamuraTRetargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificityCancer Res20066624118401185017178881
   PubMed Web of Science ®Google Scholar
• BhatRDempeSDinsartCRommelaereJEnhancement of NK cell anti-tumor responses using an oncolytic parvovirusInt J Cancer2011128490891920473905
   PubMed Web of Science ®Google Scholar
• BhatRRommelaereJNK-cell-dependent killing of colon carcinoma cells is mediated by natural cytotoxicity receptors (NCRs) and stimulated by parvovirus infection of target cellsBMC Cancer20131336723902851
   PubMed Web of Science ®Google Scholar
• DempeSLavieMStruyfSAntitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitmentCancer Immunol Immunother201261112113212322576056
   PubMed Web of Science ®Google Scholar
• OgbomoHZempFJLunXMyxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivoPLoS One201386e6682523762498
   PubMed Web of Science ®Google Scholar
• JarahianMWatzlCFournierPActivation of natural killer cells by new castle disease virus hemagglutinin-neuraminidaseJ Virol20098316810821
   Web of Science ®Google Scholar
• OgbomoHMichaelisMGeilerJTumor cells infected with oncolytic influenza A virus prime natural killer cells for lysis of resistant tumor cellsMed Microbiol Immunol201019929310120012989
   PubMed Web of Science ®Google Scholar
• WongthidaPDiazRMGalivoFType III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancerCancer Res201070114539454920484025
   PubMed Web of Science ®Google Scholar
• HeiberJFBarberGNVesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agentJ Virol20118520104401045021813611
   PubMed Web of Science ®Google Scholar
• DiazRMGalivoFKottkeTOncolytic immunovirotherapy for melanoma using vesicular stomatitis virusCancer Res200767242840284817363607
   PubMed Web of Science ®Google Scholar
• TaiLHde SouzaCTBélangerSPreventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cellsCancer Res20137319710723090117
   PubMed Web of Science ®Google Scholar
• TaiLHAuerRAttacking postoperative metastases using perioperative oncolytic viruses and viral vaccinesFront Oncol2014421725161958
   PubMedGoogle Scholar
• PrestwichRJErringtonFDiazRMThe case of oncolytic viruses versus the immune system: waiting on the judgment of SolomonHum Gene Ther200920101119113219630549
   PubMed Web of Science ®Google Scholar
• PrestwichRJErringtonFSteeleLPReciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirusJ Immunol200918374312432119734207
   PubMed Web of Science ®Google Scholar
• ErringtonFSteeleLPrestwichRReovirus activates human dendritic cells to promote innate antitumor immunityJ Immunol200818096018602618424722
   PubMed Web of Science ®Google Scholar
• ZhangJTaiLHIlkowCSMaraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic diseaseMol Ther20142271320133224695102
   PubMed Web of Science ®Google Scholar
• KomaruAUedaYFuruyaASustained and NK/CD4+ T cell-dependent efficient prevention of lung metastasis induced by dendritic cells harboring recombinant Sendai virusJ Immunol200918374211421919734206
   PubMed Web of Science ®Google Scholar
• WillmonCDiazRMWongthidaPVesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamideMol Ther201119114014920978474
   PubMed Web of Science ®Google Scholar
• FulciGBreymannLGianniDCyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProc Natl Acad Sci U S A200610334128731287816908838
   PubMed Web of Science ®Google Scholar
• GranotTVenticinqueLTsengJCMerueloDActivation of cytotoxic and regulatory functions of NK cells by Sindbis viral vectorsPLoS One201166e2059821674047
   PubMed Web of Science ®Google Scholar
• CerulloVDiaconuIRomanoVAn oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearanceMol Ther201220112076208622828500
   PubMed Web of Science ®Google Scholar
• SuzukiEKapoorVJassarASKaiserLRAlbeldaSMGemcitabine selectively eliminates splenic Gr-1+/CD11b+myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune reactivityClin Cancer Res200511186713672116166452
   PubMed Web of Science ®Google Scholar
• KottkeTGalivoFWongthidaPTreg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virusMol Ther20081671217122618431359
   PubMed Web of Science ®Google Scholar
• LaptevaNAldrichMWeksbergDTargeting the intratumoral dendritic cells by the oncolytic adenoviral vaccine expressing RANTES elicits potent antitumor immunityJ Immunother200932214515619238013
   PubMed Web of Science ®Google Scholar
• LiJLLiuHLZhangXRA phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patientsGene Ther200916337638219092859
   PubMed Web of Science ®Google Scholar
• ChoiIKLeeJSZhangSNOncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rβ2 or IL-18RαGene Ther201118989890921451575
   PubMed Web of Science ®Google Scholar
• van RikxoortMMichaelisMWolschekMOncolytic effects of a novel influenza A virus expressing interleukin-15 from the NS reading framePLoS One201275e3650622563505
   PubMed Web of Science ®Google Scholar
• StephensonKBBarraNGDaviesEAshkarAALichtyBDExpressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunityCancer Gene Ther201219423824622158521
   PubMed Web of Science ®Google Scholar
• GastonDCOdomCILiLProduction of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1PLoS One2013811e8176824312353
   PubMed Web of Science ®Google Scholar
• ChoiKJZhangSNChoiIKKimJSYunCOStrengthening of anti-tumor immune memory and prevention of thymic atrophy mediated by adenovirus expressing IL-12 and GM-CSFGene Ther201219771172321993173
   PubMed Web of Science ®Google Scholar
• LemayCGRintoulJLKusAHarnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccineMol Ther20122091791179922760544
   PubMed Web of Science ®Google Scholar
• HirvinenMHeiskanenROksanenMFc-gamma receptor polymorphisms as predictive and prognostic factors in patients receiving oncolytic adenovirus treatmentJ Transl Med20131119323965133
   PubMed Web of Science ®Google Scholar